Regeneron Up Nearly 6%, Best Performer in the Nasdaq 100 So Far Today -- Data Talk

Regeneron Pharmaceuticals, Inc. (REGN) is currently at $450.58, up $25.20 or 5.92%

-- Would be highest close since Oct. 11, 2017, when it closed at $452.97

-- On pace for largest percent increase since Nov. 5, 2019, when it rose 6.93%

-- Earlier Tuesday, Evercore ISI Group and Jefferies both upgraded their rating for Regeneron Pharma, Benzinga reported

-- Novartis' Beovu macular-degeneration treatment had some concerning safety reports, suggesting that Regeneron's Eylea alternative could command a greater market share, Barron's reported

-- Currently up four of the past five days

-- Currently up three consecutive days; up 12.89% over this period

-- Up 33.33% month-to-date; on pace for best month since Jan. 2012, when it rose 63.92%

-- Up 20% year-to-date

-- Down 23.94% from its all-time closing high of $592.40 on Aug. 5, 2015

-- Would be a new 52-week closing high

-- Up 64.77% from its 52-week closing low of $273.46 on Sept. 27, 2019

-- Traded as high as $454.08; highest intraday level since Oct. 12, 2017, when it hit $454.52

-- Up 6.75% at today's intraday high; largest intraday percent increase since Nov. 5, 2019, when it rose as much as 10.63%

-- Third best performer in the S&P 500 today

-- Best performer in the Nasdaq 100 today

All data as of 11:27:55 AM

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

February 25, 2020 11:51 ET (16:51 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.